Swiss TAVR firm attracts SwFr23m funding
This article was originally published in Clinica
Symetis, a Swiss company developing a transcatheter aortic valve replacement (TAVR) system, has attracted SwFr23m ($21.2m) in equity financing. The investment round was co-led by Wellington Partners and Vinci Capital-Renaissance PME, and included the participation of new investor Banexi Venture Partners and Symetis’ existing shareholders. The funds will be used to advance the clinical development of Symetis’ Acurate TA self-positioning TAVR system. The Lausanne-based firm is expecting to initiate its first-in-man study in the second half of 2009 and begin testing and validation of Acurate TF, a transfemoral version of the technology.